highest PSAprostate cancermetastasisyoungIntroduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed ...
PSA levels within 2 years of diagnosis do not predict lethal prostate cancer outcomesBecause of the excellent prognosis for localized prostate cancer in patients who remain untreated, early radical surgery might be unnecessary in most cases. Little is known about early indicators that might predict ...
Your Gleason score is an important part of how your doctor will assess how likely your cancer is to grow and spread. They'll consider your Gleason score along with other factors, like your PSA levels, your PSA levels over time, physical exam findings, and tumor imaging if you need it. ...
If your test shows you have a high PSA, that doesn't necessarily mean you have cancer. Your doctor will likely have you take another PSA test to make sure your level is higher than normal. Your doctor can also order other tests to help figure out why your PSA levels are high, such ...
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
Median PSA was 0.68 ng/mL in the 40 to 49 group, 0.88 ng/mL in the 50 to 54 group and 0.96 ng/mL in the 55 to 59 group. Men with PSA levels above the median had a significantly increased risk for prostate cancer in the 40 t...
This cluster randomized trial evaluates the effect of a single prostate-specific antigen (PSA) screening test on 10-year prostate cancer–specific
R. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67, 312–329 (2007). Article CAS PubMed Google Scholar Fong, L. et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 ...
WAP four-disulfide core domain 2 (WFDC2) is a small secretory protein that has been widely studied in ovarian cancer. It has been proven that WFDC2 promotes proliferation and metastasis in ovarian cancer, and serves as a diagnostic biomarker. However, the specific function of WFDC2 in prostat...
Table 1. Results of Randomized Clinical Trials of PSA-Based Screening (Key Question 1)a View LargeDownload SourceNo. of ParticipantsAge Range, yPSA Screening Threshold, ng/mLScreening Interval, y (Planned No. of Screening Rounds)Median Follow-up, yProstate Cancer Incidence, No. (%)No. of Pr...